Buprenorphine has been in clinical use in anaesthesia for several decades. Recently, the high-dose sublingual formulation (Subutex®, Reckitt Benckiser, Slough, U.K.) has been increasingly used as maintenance therapy in opioid dependence, as an alternative to methadone and other pharmacological therapies. Buprenorphine has unique pharmacological properties making it well suited for use as a maintenance therapy in opioid dependence. However, these same properties may cause difficulty in the perioperative management of pain. Buprenorphine is a partial opioid agonist, attenuating the effects of supplemental illicit or therapeutic opioid agonists. As a result of its high receptor affinity, supplemental opioids do not readily displace buprenorphine from the opioid receptor in standard doses. High-dose buprenorphine has an extended duration of action that prolongs both of these effects.
Buprenorphine is a partial opioid agonist, which has been used for decades as an analgesic. The pharmacokinetic and pharmacodynamic properties of this drug have been extensively studied. Buprenorphine's analgesic use has generally been limited to the 0.2 mg sublingual tablet (Temgesic®, Reckitt Benckiser, Slough, U.K.).
More recently, buprenorphine has become available as a 4 mg sublingual tablet (Subutex®, Reckitt Benckiser, Slough, U.K.) for use in opioid substitution. This product was listed by the Australian Pharmaceutical Benefits Scheme (PBS) in August 2001 as a maintenance therapy for people with opioid dependence 1 . Since then, it has been increasingly used in this setting. Prior to its marketing in Australia, considerable experience with this high-dose formulation was gained overseas, particularly in France.
Analgesia for patients stabilized on the high-dose formulation can be difficult, with attenuation of the effects of supplemental opioids by buprenorphine's properties of partial agonism and strong receptor affinity. This is further complicated by Subutex's ® extended duration of action compared to Temgesic®. There are few guidelines for the perioperative management of these patients and there has been minimal research in this area. Clinicians may encounter patients stabilized on high dose buprenorphine presenting for elective or emergency surgery, each requiring an individualized pain management plan.
The purpose of this paper is to review the use, pharmacokinetics, and pharmacodynamics of Subutex ®. We will also highlight difficulties in the control of pain in patients stabilized on the higher dosage formulation, and provide suggestions for management.
OPIOID ABUSE IN AUSTRALIA
Opioid addiction continues to be an increasing problem in Australia, with well-recognised medical and social complications. In Australia there are estimated to be more than 70,000 opioid dependent people, more than double that in the mid-1980s 2 .
MAINTENANCE THERAPIES-AIMS AND OPTIONS
An effective substitution programme decreases the use of, and craving for, illicit opioids. Advantages include a decrease in blood-borne infections, improved employment and social adjustment with reduced death and crime rates. The stability afforded by longterm substitution programmes allows some of these problems to be addressed with a significant improvement in clinical outcomes 3 .
There are a range of pharmacological treatments used in the management of opioid addiction, including opioid agonists (primarily methadone), partial agonists (buprenorphine), or antagonists 3, 4 . The aim of pharmacological treatment with opioid agonists is to replace the short-acting parenteral opioid with a longer-acting oral agent, reducing the need for illicit drugs and preventing opioid withdrawal symptoms 5 . Methadone maintenance treatment (MMT) has been available since the 1970s, and is the most common maintenance treatment in Australia. It retains more heroin users than competing drug-free forms of treatment, decreasing heroin use and complications, as well as being cost-effective 4,6-8 . Thus it has received government support. The opioid antagonist naltrexone has been tried, but data supporting its use are lacking 9 .
Problems with MMT include stigma, daily dosing, difficulty withdrawing from the treatment, and deaths. The death rate from MMT is less than that of uncontrolled heroin use, and tends to occur either on starting therapy, or when the patient is seeking to withdraw from methadone. Deaths have also been noted in patients and non-patients from abuse of diverted take-home methadone (particularly where the policy for take-away doses is liberal), or where there is ongoing abuse of other drugs, including opioids and benzodiazepines 3, [5] [6] [7] .
Controlled clinical trials have demonstrated buprenorphine to be an effective maintenance therapy for opioid dependence 3, 8, 10, 11 . It is perceived to have less adverse effects and social stigma than methadone 4 . In 1996, France permitted buprenorphine to be prescribed by any physician for the maintenance of opioid-dependent patients, mainly as a result of the perceived safety of this drug. This improved access, convenience, and therefore uptake by clients was followed by a decrease in heroin-associated deaths, and a general decline in heroin use 3, 4, 7, 10, 12 . The liberal policy on supervised administration has encouraged the development of a black market for take-home doses and diversion to intravenous administration. Abuse of buprenorphine through intravenous administration is minimized by co-formulation with naloxone (Suboxone®). This does not compromise sublingual efficacy (naloxone is ineffective by this route) but induces withdrawal when administered intravenously, deterring abuse of the tablet preparation by this route 10 . This combination formulation is available in the United States and is expected to be available in Australia at the end of the year.
In Australia, the guidelines for use of buprenorphine as a maintenance therapy differ from those in France. For example, in the State of Victoria, doctors must be accredited to prescribe buprenorphine, and all doses are supervised-ie. take-home doses are not allowed.
DOSE AND ADMINISTRATION OF BUPRENORPHINE
Buprenorphine doses of 0.2-0.6 mg four times daily are used for the treatment of pain 13 . In contrast, doses of 8-32 mg every 2-3 days are effective in opioid maintenance therapy 5, 10, [14] [15] [16] [17] . Doses greater than 16 mg appear to add little additional opioid agonist effect yet prolong the elimination half-life and duration of action, thereby allowing the convenience of alternate day dosing, or even third daily dosing in some patients 8, 10, 14 . Dosing schedules vary enormously, with some patients requiring daily doses. Clinically, intravenous buprenorphine has a potency of 25-40 compared to intravenous morphine 18 .
PHARMACOLOGY
The mu-opioid (µ, OP3) receptor is central to pain and opioid addiction systems, with chronic administration of µ-opioid agonists inducing analgesic tolerance and physical dependence 19, 20 . Kappa-opioid (κ, OP2) receptor stimulation is associated with dysphoria and sedation, delta-opioid (δ, OP1) receptor agonists potentiate µ-opioid effects (particularly physical dependence and tolerance), while ORL-1 (NOP, OP4, nociceptin/orphanin FQ,) receptors appear to antagonise µ-opioid effects amongst other inhibitory effects [20] [21] [22] [23] .
Both agonist and antagonist effects have been demonstrated by buprenorphine or its active metabolite norbuprenorphine at µ-, κand δ-opioid receptors, and ORL-1 receptors 21, 24, 25 . Opposing pharmacological effects and variable potency have been noted between in vitro studies, which may be a result of the different procedures used 21, 22 . The potency of receptor binding also varies between in vitro and in vivo studies 21, 24, 25 .
The lower level of physical dependence attributed to buprenorphine 8, 15, 26 probably reflects the pharmacological predominance of partial µ-opioid agonist, δ-opioid antagonist and ORL-1 agonist properties 21, 24 .
Short-term animal studies have demonstrated buprenorphine's bell-shaped dose-response curve to opioid effects, with decreased agonist effects at high doses, as represented in Figure 1 24, 26, 27 . This represents a complex interplay between dose-related pharmacological effects of buprenorphine and norbuprenorphine at opioid receptors 21, 22, 24 . In vivo, µ-and κ-opioid effects are seen in the dose range of ~0.01-0.5 mg/kg, compared to δ-opioid effects at ~0.5-10 mg/kg 21, 26 , although this may vary 28 . The dose required for δ-opioid antagonist effects appears beyond those prescribed for maintenance therapy, which may explain why physical dependence and tolerance can develop with chronic buprenorphine use 21, 24 . ORL-1 effects at higher doses may be an important mediator of buprenorphine's ceiling effect in vivo 22, 24 .
Buprenorphine is a partial agonist, also known as a mixed agonist-antagonist. Traditional pharmacological theory describes the binding of a ligand to a specific receptor to produce an effect. This effect depends on the concentration of ligand, where the higher the number of receptors occupied by a ligand, the greater the effect. However there appears to be little correlation between receptor affinity and the clinical effect of µ-opioid receptor agonists, including buprenorphine 29 . Buprenorphine may bind to a receptor target that differs from other opioid agonists, inducing a particular conformation change and an individual pharmacological effect 30 . Despite increases in the dose of buprenorphine, there is minimal additional opioid effect 21, 27 . This "ceiling effect" is characteristic of partial agonists.
PROPERTIES OF HIGH-DOSE BUPRENORPHINE
Buprenorphine has an extended duration of action, related to both the apparent half-life of the parent drug and the high-affinity and slow dissociation of buprenorphine from the µ-receptor 3, 4, 14, 26, 31 . The high affinity and slow dissociation of buprenorphine from opioid receptors reduces the effect of supplemental opioids, and explains the poor correlation between plasma concentrations and opioid effects 4, 13, 32 . The interplay of buprenorphine's pharmacokinetic and pharmacodynamic properties must be understood to adequately manage the perioperative pain of patients stabilized on this treatment.
PHARMACOKINETICS

Absorption
Buprenorphine has an extensive first pass elimination, with an oral bioavailability estimated at 3-6% 33 . Its lipophilicity allows sublingual administration 13, 34 . Early sublingual preparations were alcohol based, but these have now been replaced by tablet formulation. These preparations differ in sublingual bioavailability, so that equal sublingual doses of liquid and tablet do not produce equivalent plasma drug plasma concentrations 17, 35 . Sublingual tablets have a bioavailability of approximately 30-35% compared to the intravenous formulation, or about 50-80% of the sublingual alcohol preparation 13, 14, 17, 31, 34, 36 . Clinically, 12 mg of buprenorphine in tablet formulation (as available in Australia) is roughly equivalent to 8 mg of liquid 14 .
DISTRIBUTION
Buprenorphine is both lipophilic and highly protein bound, with a volume of distribution greater than 200 litres. Buprenorphine distributes to fat tissue and slowly redistributes to plasma, extending the elimination half-life regardless of the route of administration 14, 29, 31, 33, 37 . In rats, buprenorphine readily 19 IMPACT OF BUPRENORPHINE ON crosses the blood-brain barrier while norbuprenorphine does not 28 .
METABOLISM AND EXCRETION
Buprenorphine is metabolized in the liver, primarily through conjugation to the inactive compound buprenorphine-3-glucuronide 29, 33, 38, 39 . To a lesser degree, buprenorphine is also oxidized by the liver enzyme CYP450 3A4 to the N-dealkylated product norbuprenorphine 40 . Norbuprenorphine has some opioid activity (although less than buprenorphine), but its potency varies between studies and its clinical significance is unclear 24, 28, 31, 41 . Norbuprenorphine's plasma concentration may exceed that of buprenorphine at steady state, at which point its clinical effects may become more significant 42 . As a result, the pharmacological effects seen with maintenance dosing in humans may differ from those in short-term animal studies. However, since norbuprenorphine appears to penetrate the blood brain barrier to only a limited degree, its therapeutic importance is probably limited 28 . Short-or long-term co-administration of inhibitors (e.g. erythromycin or ketoconazole), or inducers (e.g. carbamazepine) of CYP450 3A4, may alter the metabolism and therapeutic effect of buprenorphine 43 . Both metabolites are excreted primarily in the bile and eliminated in the faeces 29, 33, 36, 38 . Enterohepatic recirculation occurs to a degree 33, 38, 39 , which may contribute to increased norbuprenorphine plasma concentrations with maintenance dosing.
Elimination Half-life
Buprenorphine has a half-life that varies with both the dose and route of administration. Generally, high dose buprenorphine used for opioid substitution has an apparent half-life of 20-70 hours 14 . This is in contrast to the shorter half-life of 2-6 hours noted in doses used for analgesia 14, 32, 36 . Route of administration is also important, with marked differences in elimination half-life (almost 10-fold) between intravenous and sublingual preparations. This has been attributed to a slow, rate-limited release of buprenorphine from the oral mucosa. 31 Other differences in half-life noted in the literature are attributed to variability in the dose administered and inconsistency in trial designs, including differences in formulation, inappropriate analytical techniques, or limited duration of sampling. 31, 37 
PHARMACODYNAMICS
Ceiling Effects and Respiratory Depression
Buprenorphine's ceiling effect minimizes opioid toxicity despite escalating doses. Although it is approached with sublingual doses of 8-16 mg 17, 27, 44, 45 , the dose corresponding to an absolute ceiling effect has not been determined in humans 17, 27 . The ceiling effect limits the abuse potential and minimizes respiratory depression with high doses, extending the safety margin 4, 6, 8, 15, 27, 44 . Even where the dose is raised from 0.02 mg to 32 mg in non-dependent humans, respiratory depression does not occur 46 . However, deaths from buprenorphine have been reported, and while it has been suggested that concomitant benzodiazepines were responsible for these deaths, individual sensitivity to buprenorphine toxicity cannot be excluded 47 . Rat studies suggest that the direct effect of norbuprenorphine in the lungs is more important than a combined central effect with buprenorphine in the development of respiratory depression 28 . This may be particularly significant during maintenance therapy where norbuprenorphine plasma concentrations are increased, as discussed above. It is not known whether tolerance develops, or if there is an increased risk of respiratory depression with high norbuprenorphine plasma concentrations at steady state.
RECEPTOR AFFINITY AND INTERACTION WITH OTHER OPIOIDS
Buprenorphine has strong receptor affinity, particularly at µ-receptors, where 0.032 mg/kg of buprenorphine blocks the opioid effects from up to 3.2 mg/kg of morphine in monkeys 21 . Clinical studies have demonstrated opioid effects when supplemental opioids agonists have been administered to patients receiving high dose buprenorphine 17, 27, 45 . This reaffirms the observation that buprenorphine does not exert an absolute ceiling effect at high doses, but instead attenuates the effect of other opioid agonists. This property is useful for patients on a maintenance program, because it minimizes the euphoriant effect of concurrently administered opioids, discouraging the likelihood of ongoing opioid abuse.
The receptor affinity of buprenorphine is sufficiently strong such that it can displace other recently administered opioid agonists and precipitate a withdrawal reaction 15, 26, 44 . Withdrawal reactions have been noted when buprenorphine is administered to patients stabilized on more than 40 mg of methadone per day 48 , or after the first dose of buprenorphine at initiation of maintenance therapy, if the dose is given too soon after the patient last used opioids 49 .
Buprenorphine's strong receptor affinity with partial agonism has also led to its use in opioid detoxification 46, 49, 50 . It may also have a role in the treatment of acute opioid overdose for the same reason. 20 
D. M. ROBERTS, M. MEYER-WITTING INTERACTION WITH OTHER CNS DEPRESSANTS
Despite the safety margin conferred by the ceiling effect, death has been noted from overdose with buprenorphine. This has predominantly occurred as a result of prolonged respiratory depression when co-administered with sedatives, particularly benzodiazepines 4 . While buprenorphine may weakly inhibit CYP3A activity, decreasing the clearance of some benzodiazepines, this is noted only in doses far exceeding its therapeutic concentrations 51, 52 . These deaths are more likely to be due to an additive pharmacodynamic interaction, as previously observed in anaesthetic practice 53 . Despite the high prevalence of concomitant buprenorphine and benzodiazepine use in the community, deaths are infrequent, suggesting an idiosyncratic interaction. Given buprenorphine's strong receptor affinity, naloxone in standard doses is unlikely to be useful in the resuscitation of these patients 26, 43 , although efficacy has been reported when higher doses have been administered (L Murray, Personal Communication).
PAIN MANAGEMENT ISSUES
The perioperative management of patients with a history of opioid abuse can be a challenge, particularly in the absence of clear consensus guidelines 54 . While treating physicians may be wary of the patient misrepresenting their level of pain as a form of substance-seeking behaviour, this is generally unwarranted 55 .
Hyperalgesia may be noted in patients with a history of previous opioid use, requiring higher doses of opioids for adequate pain control than those without such a history 54, 56 . The mechanism of action of hyperalgesia is not entirely clear, but may include chronic opioid-induced receptor changes. Theoretically, partial agonists such as buprenorphine may induce less hyperalgesia than full agonists, although this has yet to be confirmed. It is unclear how much time is required to reverse this following abstinence from opioids. Drug-free former opioid addicts have been shown to tolerate pain and respond to analgesia better than MMT patients 19 .
An alternative explanation is that poor pain tolerance is an inherent feature of these patients, making them susceptible to drug addiction 19, 54 .
Reports of pain in this population should be assessed and treated with an appropriate strategy to provide adequate relief 55 . Pain scores may not be the best tool to assess efficacy of an analgesic regimen. Instead, more objective assessments of function, such as the ability to cough or mobilize may be more appropriate 54, 55, 57 . As for all patients, inadequate pain relief (especially if the patient perceives their subjective pain is not taken seriously by their carers) may lead to poor postoperative recovery, in addition to fostering anxiety, drug-seeking behaviours and demands 57 . A fine line needs to be drawn between taking the patient's subjective responses seriously and acquiescing to unreasonable demands.
APPROACH TO POSTOPERATIVE PAIN MANAGEMENT IN PATIENTS STABILIZED ON BUPRENORPHINE
The global aim of treatment of the drug dependent patient is to 55,57 : 1. Identify that the patient is drug dependent. Ideally this should occur prior to surgery through preadmission clinics, or at the time of admission. 2. Where possible liaise with hospital-based alcohol and drug services to determine the patient's opioid maintenance requirements and to formulate an agreed management plan. This should also involve communication with the patient's regular buprenorphine prescriber. Questions of concern include the dose of drug the patient is receiving, whether the patient has been stable on this medication, and whether the patient is in the induction, maintenance, or withdrawal phase of substitution therapy. It is particularly important to find out from the pharmacy when the patient last picked up their dose, as irregular pickups and no pickups in the last three days calls for a reassessment of the degree of tolerance, and a possible reduction in the maintenance dose. 3. Maintain the comfort and dignity of the patient through:
• provision of optimal analgesia to facilitate recovery and regular review of this regimen • Foster patient cooperation through respectful communication, education regarding realistic postoperative treatment endpoints, and encouragement of their participation in decision making. • Prevention of opioid withdrawal • Vigilance to the possibility of ongoing illicit or other drug-taking • Monitoring for withdrawal from other drugs • Setting appropriate boundaries on unreasonable demands, expectations or behaviour, through firm but flexible negotiation • Attending to other co-morbidities associated with opioid dependence.
MANAGEMENT OF PAIN SPECIFICALLY
The approach to analgesia in patients stabilized on buprenorphine is similar in principle to that of other patients, using multimodal analgesia in conjunction with non-pharmacological techniques 14, [55] [56] [57] . The following guidelines are an opinion, based on clinical experience from several acute pain services, and recommendations from the literature. They are discussed here and summarized in Table 1 .
Pharmacological Techniques a) Maximize non-opioid analgesia, including regular paracetamol and/or non-steroidal anti-inflammatory drugs as appropriate b) Local anaesthetic techniques including infiltration, regional and neuraxial blocks c) Opioids (usually intravenous) administered with caution. This is discussed further below. Non-pharmacological techniques: d) Adjunctive therapeutic options include transcutaneous electrical nerve stimulation (TENS), local heat/cold treatment, acupuncture, hypnosis and massage.
In addition to maximizing these techniques, specific management strategies depend on the type of surgery:
• Elective Admissions-Minor Operations/Day Cases a) Continue current regimen of buprenorphine. Increasing the maintenance dose by 25% may assist pain control and allow the patient to remain on buprenorphine 56 . Because buprenorphine is a partial agonist, the analgesic efficacy of this increased dose is not readily predictable but may be effective. b) Where pain may not be controlled by these techniques, the patient should be managed as per major operations.
• Elective Admissions-Major Operations Alternative management strategies: a) Increase the current dose of buprenorphine by 25%, and administer supplemental intravenous opioids as required for residual pain 56 . Since most patients are stabilized on doses higher than 8-12 mg, buprenorphine's partial-agonist properties may reduce the effect of additional intravenous or oral opioids. The baseline analgesia provided by this dose may suffice to treat significant levels of pain. Where this is inadequate, titration of high doses of full agonist opioids (e.g. morphine or fentanyl) may surpass this blockade to a degree, but this requires close monitoring in a highdependency unit (HDU). The dose of opioid required is the dose that controls the pain without excessive sedation or respiratory depression of the patient. These effects must be monitored carefully, which is probably best achieved in a HDU.
Converting the patient to a full opioid agonist (e.g. methadone or morphine) prior to surgery is an attractive but potentially complicated option. It should perhaps be reserved for special circumstances where there is no alternative. For example, this option is recommended if sublingual administration during the perioperative period is not possible, given the major pharmacokinetic differences (notably elimination half-life) between the intravenous and sublingual administration of buprenorphine 31 . It allows additional pure opioid agonists to be titrated postoperatively as required, once the buprenorphine has worn off (which may take up to 72 hours) without the complication of opioid blockade. This conversion is complicated due to the long but unpredictable half-life of both buprenorphine and methadone from factors including patient age, dose-dependency and variable absorption. Dose equivalents of high-dose buprenorphine with morphine or methadone are not clear 45 , so conversion to a full agonist is not recommended without advice from experts in this field. If conversion to a full opioid agonist is essential, and expert help is not available, the following doses may be used as a guide, based on guidelines used by alcohol and drug dependency units 14 . Since buprenorphine dose-equivalents are unpredictable, the importance of close monitoring and careful titration of additional doses of the full agonist is emphasised. * A full agonist may be commenced 24 hours after the last dose of buprenorphine. * Patients requiring 4mg or less of buprenorphine should be started on methadone 20 mg daily (or 60mg daily of sustained-release morphine) 58 , while those requiring more than 4 mg of buprenorphine, an initial daily dose of 40 mg is recommended (or 80 mg daily of sustained-release morphine) 58 . This dose is carefully adjusted over a number of days to avoid opioid withdrawal symptoms. Additional morphine (oral or parenteral) or fentanyl can be given when needed for breakthrough pain, as per usual practice. Once postoperative analgesia is no longer required, buprenorphine may be recommenced (see below).
• Acute or Emergency Admissions
The identification of patients stabilized on buprenorphine who are admitted acutely present another challenge, particularly where their level of conscious-ness is depressed. The higher the buprenorphine dose, the longer the duration of action of the buprenorphine. Since the duration of action correlates with the dose interval, this information is most helpful in this scenario.
It is important to remember that the dose requirement of morphine may drop as the buprenorphine dissociates from the µ-receptor, which may take 24-72 hours after the last dose.
The ongoing pain management of these patients is as outlined above.
DISCHARGE FROM HOSPITAL
• Once the postoperative analgesic requirements are minimal, the patient can then be transferred back to their preoperative buprenorphine dosing regimen 14 . Early re-introduction of buprenorphine may precipitate a withdrawal syndrome. This may be minimized by withholding all opioids until symptoms of withdrawal develop, usually about eight hours after the last dose. Buprenorphine may then be recommenced. The patient's pain relief should continue to be monitored carefully. • The patient should be stabilized on their usual dose of buprenorphine (±simple analgesics) at the time of discharge. • The patient's usual buprenorphine prescriber and dispensing pharmacist should be notified of the outcomes of surgery, current analgesic requirements, and details of the last dose of buprenorphine administered. Particular care should be taken that the patient either does not receive a double dose, or that their ongoing supply it is not mistakenly omitted on the day of discharge. Careful and complete communication with community prescribers is essential. Ongoing review should also be arranged, which may be in conjunction with hospital-based alcohol and drugs services.
CONCLUSION
There is increasing use of high-dose buprenorphine for opioid maintenance therapy. The pharmacokinetic and pharmacodynamic properties of this product may complicate the perioperative management of pain, particularly due to its extended duration of action and partial opioid agonist properties. This may attenuate effects of supplemental opioids, resulting in poor pain control. An emphasis on nonopioid analgesics and non-pharmacological techniques is a priority. Where pain may not be adequately relieved by these methods, several options are available. These include continuation of buprenor-phine with treatment of breakthrough pain by additional buprenorphine and/or bolus doses of full opioid agonists, or timely cessation of buprenorphine and conversion to a full opioid agonist. It is important that these patients are carefully monitored to prevent excess sedation, respiratory depression or opioid withdrawal.
